

Rainer Hinz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6132390/publications.pdf>

Version: 2024-02-01

100
papers

4,513
citations

101535

36
h-index

106340

65
g-index

108
all docs

108
docs citations

108
times ranked

6370
citing authors

#	ARTICLE	IF	CITATIONS
1	Microglia, amyloid, and cognition in Alzheimer's disease: An [¹¹ C](R)PK11195-PET and [¹¹ C]PIB-PET study. <i>Neurobiology of Disease</i> , 2008, 32, 412-419.	4.4	448
2	Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. <i>Biological Psychiatry</i> , 2018, 83, 61-69.	1.3	266
3	Reference and target region modeling of [¹¹ C]-(R)-PK11195 brain studies. <i>Journal of Nuclear Medicine</i> , 2007, 48, 158-67.	5.0	216
4	Microglia, Amyloid, and Glucose Metabolism in Parkinson's Disease with and without Dementia. <i>Neuropsychopharmacology</i> , 2013, 38, 938-949.	5.4	202
5	Brain inflammation is induced by co-morbidities and risk factors for stroke. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1113-1122.	4.1	173
6	Increased 5-HT _{2A} Receptor Binding in Euthymic, Medication-Free Patients Recovered From Depression: A Positron Emission Study With [¹¹ C]MDL 100,907. <i>American Journal of Psychiatry</i> , 2006, 163, 1580-1587.	7.2	170
7	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 104-114.	6.4	170
8	P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. <i>Lancet Neurology</i> , The, 2013, 12, 777-785.	10.2	155
9	Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease. <i>Brain</i> , 2017, 140, 2002-2011.	7.6	147
10	Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease. <i>Brain</i> , 2018, 141, 2740-2754.	7.6	143
11	Optimization of Supervised Cluster Analysis for Extracting Reference Tissue Input Curves in [¹¹ C]PK11195 Brain PET Studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1600-1608.	4.3	120
12	On the Undecidability among Kinetic Models: From Model Selection to Model Averaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2003, 23, 490-498.	4.3	115
13	Upregulation of opioid receptor binding following spontaneous epileptic seizures. <i>Brain</i> , 2007, 130, 1009-1016.	7.6	101
14	Flutriciclamide (¹⁸ F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1753-1759.	5.0	93
15	Effects of Citalopram Infusion on the Serotonin Transporter Binding of [¹¹ C]DASB in Healthy Controls. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 1478-1490.	4.3	89
16	In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [¹¹ C](R)-PK11195 positron emission tomography study. <i>Molecular Psychiatry</i> , 2016, 21, 1672-1679.	7.9	82
17	The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An [¹¹ C]-(R)-PK11195 PET Imaging and Neuropathology Study. <i>Journal of Nuclear Medicine</i> , 2015, 56, 512-517.	5.0	77
18	Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. <i>Neurology</i> , 2019, 92, e1331-e1343.	1.1	69

#	ARTICLE	IF	CITATIONS
19	Detection and Quantification of Large-Vessel Inflammation with ¹¹ C-(R)-PK11195 PET/CT. <i>Journal of Nuclear Medicine</i> , 2011, 52, 33-39.	5.0	68
20	5-HTT Binding in Recovered Depressed Patients and Healthy Volunteers: A Positron Emission Tomography Study With [¹¹ C]DASB. <i>American Journal of Psychiatry</i> , 2007, 164, 1858-1865.	7.2	66
21	Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [¹¹ C]DASB. <i>Psychopharmacology</i> , 2011, 213, 555-562.	3.1	65
22	Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma. <i>Neuro-Oncology</i> , 2019, 21, 314-325.	1.2	59
23	Comparative Evaluation of Three TSPO PET Radiotracers in a LPS-Induced Model of Mild Neuroinflammation in Rats. <i>Molecular Imaging and Biology</i> , 2017, 19, 77-89.	2.6	58
24	[¹¹ C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1406-1419.	6.4	55
25	Reproducibility of [¹¹ C]Choline-Positron Emission Tomography and Effect of Trastuzumab. <i>Clinical Cancer Research</i> , 2010, 16, 4236-4245.	7.0	52
26	Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET. <i>NeuroImage</i> , 2013, 70, 423-433.	4.2	52
27	Microglial activation, white matter tract damage, and disability in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2018, 5, e443.	6.0	51
28	Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease. <i>Movement Disorders</i> , 2021, 36, 774-779.	3.9	49
29	The EMIF-AD PreclinAD study: study design and baseline cohort overview. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 75.	6.2	48
30	Balancing bias, reliability, noise properties and the need for parametric maps in quantitative ligand PET: [¹¹ C]diprenorphine test-retest data. <i>NeuroImage</i> , 2007, 38, 82-94.	4.2	46
31	Validation of a Tracer Kinetic Model for the Quantification of 5-HT _{2A} Receptors in Human Brain with [¹¹ C]MDL 100,907. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 161-172.	4.3	46
32	Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study. <i>Neurobiology of Disease</i> , 2018, 117, 211-216.	4.4	46
33	Brain serotonin transporter binding in former users of MDMA (ecstasy). <i>British Journal of Psychiatry</i> , 2009, 194, 355-359.	2.8	45
34	Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using ¹¹ C-BU99008 PET and its relationship with amyloid load. <i>Molecular Psychiatry</i> , 2021, 26, 5848-5855.	7.9	43
35	Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸ F-FAHA. <i>NeuroImage</i> , 2013, 64, 630-639.	4.2	42
36	Pre- and Postsynaptic Serotonergic Differences in Males with Extreme Levels of Impulsive Aggression Without Callous Unemotional Traits: A Positron Emission Tomography Study Using ¹¹ C-DASB and ¹¹ C-MDL100907. <i>Biological Psychiatry</i> , 2012, 72, 1004-1011.	1.3	41

#	ARTICLE	IF	CITATIONS
37	¹⁸ F-Florbetapir PET in Patients with Frontotemporal Dementia and Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2015, 56, 386-391.	5.0	41
38	Rank-shaping regularization of exponential spectral analysis for application to functional parametric mapping. <i>Physics in Medicine and Biology</i> , 2003, 48, 3819-3841.	3.0	36
39	Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans?. <i>NeuroImage</i> , 2012, 60, 1716-1723.	4.2	36
40	Presynaptic 5-HT1A is Related to 5-HTT Receptor Density in the Human Brain. <i>Neuropsychopharmacology</i> , 2011, 36, 2258-2265.	5.4	35
41	Neuroinflammation as measured by positron emission tomography in patients with recent onset and established schizophrenia: implications for immune pathogenesis. <i>Molecular Psychiatry</i> , 2021, 26, 5398-5406.	7.9	34
42	Positron emission tomography imaging of the serotonin transporter in the pig brain using [11C](+)-McN5652 and S-([18F]fluoromethyl)-(+)-McN5652. <i>Synapse</i> , 2003, 47, 143-151.	1.2	32
43	Quantification of Ligand PET Studies using a Reference Region with a Displaceable Fraction: Application to Occupancy Studies with [11C]-DASB as an Example. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 70-80.	4.3	30
44	Kinetic modeling and parameter estimation of TSPO PET imaging in the human brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 246-256.	6.4	27
45	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. <i>BMC Geriatrics</i> , 2018, 18, 289.	2.7	25
46	[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 657-662.	0.9	24
47	Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility. <i>NeuroImage</i> , 2009, 48, 329-338.	4.2	23
48	Parametric mapping using spectral analysis for 11C-PBR28 PET reveals neuroinflammation in mild cognitive impairment subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1432-1441.	6.4	22
49	Simplified quantification of 5-HT2A receptors in the human brain with [11C]MDL 100,907 PET and non-invasive kinetic analyses. <i>NeuroImage</i> , 2010, 50, 984-993.	4.2	21
50	Age-Dependent Effects of Severe Traumatic Brain Injury on Cerebral Dopaminergic Activity in Newborn and Juvenile Pigs. <i>Journal of Neurotrauma</i> , 2004, 21, 1076-1089.	3.4	19
51	Relationship between astrocyte reactivity, using novel 11C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals. <i>Molecular Psychiatry</i> , 2022, 27, 2019-2029.	7.9	19
52	Wavelet variance components in image space for spatiotemporal neuroimaging data. <i>NeuroImage</i> , 2005, 25, 159-168.	4.2	18
53	Preferred transport of O-(2-[18F]fluoroethyl)-d-tyrosine (d-FET) into the porcine brain. <i>Brain Research</i> , 2007, 1147, 25-33.	2.2	18
54	Dual-phase [18F]florbetapir in frontotemporal dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 304-311.	6.4	18

#	ARTICLE	IF	CITATIONS
55	Test-retest reproducibility of quantitative binding measures of [¹¹ C]Ro15-4513, a PET ligand for GABA A receptors containing alpha5 subunits. <i>NeuroImage</i> , 2017, 152, 270-282.	4.2	17
56	Accurate markerless respiratory tracking for gated whole body PET using the Microsoft Kinect. , 2012, , .		16
57	Challenges of quantification of TSPO in the human brain. <i>Clinical and Translational Imaging</i> , 2015, 3, 403-416.	2.1	16
58	A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia</i> , 2019, 15, 1081-1103.	0.8	16
59	Assessing Inflammation in Acute Intracerebral Hemorrhage with PK11195 PET and Dynamic Contrast-Enhanced MRI. , 2018, 28, 158-161.		15
60	In vivo quantification of glial activation in minipigs overexpressing human Î±-synuclein. <i>Synapse</i> , 2018, 72, e22060.	1.2	15
61	P-glycoprotein overactivity in epileptogenic developmental lesions measured in vivo using (R)-[¹¹ C]verapamil PET. <i>Epilepsia</i> , 2020, 61, 1472-1480.	5.1	15
62	Effect of hypoxia/hypercapnia on metabolism of 6-[¹⁸ F]fluoro-l-DOPA in newborn piglets. <i>Brain Research</i> , 2002, 934, 23-33.	2.2	14
63	Brain inflammation and psoriasis: a [¹¹ C]-(R)-PK11195 positron emission tomography study. <i>British Journal of Dermatology</i> , 2016, 175, 1082-1084.	1.5	14
64	Performance of a modified supervised cluster algorithm for extracting reference region input functions from (R)-[¹¹ C]PK11195 brain PET studies. , 2008, , .		13
65	The effect of ¹⁸ F-florbetapir dose reduction on region-based classification of cortical amyloid deposition. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2144-2149.	6.4	11
66	Comment on "In Vivo [¹⁸ F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primates". <i>ACS Chemical Neuroscience</i> , 2019, 10, 768-772.	3.5	11
67	The design and initial calibration of an optical tracking system using the Microsoft Kinect. , 2011, , .		10
68	Realtime markerless rigid body head motion tracking using the Microsoft Kinect. , 2012, , .		9
69	Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 327-332.	2.4	9
70	Technical aspects of amyloid imaging for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 25.	6.2	8
71	Developmental changes in the activities of aromatic amino acid decarboxylase and catechol-O-methyl transferase in the porcine brain: A positron emission tomography study. <i>Neuroscience Letters</i> , 2004, 364, 159-163.	2.1	6
72	Tau Aggregation Correlates with Amyloid Deposition in Both Mild Cognitive Impairment and Alzheimer's Disease Subjects. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 455-465.	2.6	6

#	ARTICLE	IF	CITATIONS
73	Îlpha 5 subunit-containing GABAA receptors in temporal lobe epilepsy with normal MRI. Brain Communications, 2021, 3, fcaa190.	3.3	5
74	Positron emission tomography to image cerebral neuroinflammation in ischaemic stroke: a pilot study. Efficacy and Mechanism Evaluation, 2020, 7, 1-26.	0.7	5
75	Resistance of brain glucose metabolism to thiopentalâ€induced CNS depression in newborn piglets. International Journal of Developmental Neuroscience, 2013, 31, 157-164.	1.6	4
76	Simplifying [18F]GE-179 PET: are both arterial blood sampling and 90-min acquisitions essential?. EJNMMI Research, 2018, 8, 46.	2.5	4
77	Amyloid-PETâ€™Positive Patient With bvFTD. Neurology: Clinical Practice, 2021, 11, e952-e955.	1.6	4
78	Tariquidar inhibition of P-glycoprotein activity in patients with temporal lobe epilepsy measured with PET and (R)-[C-11]Verapamil. NeuroImage, 2010, 52, S148.	4.2	3
79	P2-179: DOES CEREBRAL GLUCOSE METABOLISM AND BLOOD FLOW DISSOCIATE IN EARLY STAGES OF ALZHEIMER'S DISEASE?. , 2014, 10, P536-P536.		2
80	Decreased GABA-A Receptor Binding in Association With Î²-Lactam Antibiotic Use. Clinical Nuclear Medicine, 2019, 44, 981-982.	1.3	2
81	Towards improved test-retest reliability in quantitative ligand PET: [11C]Diprenorphine as an example. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S665-S665.	4.3	2
82	Image space identification of a motion tracking tool in PET and PET/CT. , 2010, , .		1
83	Optimization of high resolution PET iterative reconstruction with resolution modeling for image derived input function. , 2012, , .		1
84	Multiple target marker tracking for real-time, accurate, and robust rigid body motion tracking of the head for brain PET. , 2013, , .		1
85	Microglial activation in normal-appearing brain regions of patients with cerebral glioma: a cross-sectional study. Lancet, The, 2017, 389, S92.	13.7	1
86	[O3â€™O9â€™O3]: MICROGLIAL ACTIVATION IS ASSOCIATED WITH HIGHER GREY MATTER DENSITY AND HIPPOCAMPAL VOLUME IN MCI SUBJECTS. Alzheimer's and Dementia, 2017, 13, P921.	0.8	1
87	Parametric imaging of [11C]PIB studies using spectral analysis. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S590-S590.	4.3	1
88	Different patterns of PIB uptake in AD patients. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S666-S666.	4.3	1
89	Quantitative kinetic modelling and mapping of cerebral glucose transport and metabolism using glucoCESL MRI. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 2066-2079.	4.3	1
90	In how many kinetic classes can [lt;sup>11&/sup>C]-(R)-PK11195 brain PET data be segmented?. , 2008, , .		0

#	ARTICLE	IF	CITATIONS
91	Quantification of PET studies using a displaceable reference: Application to occupancy studies with [11C]-DASB as an example. <i>NeuroImage</i> , 2010, 52, S195-S196.	4.2	0
92	A POSITRON EMISSION TOMOGRAPHY STUDY OF [18F]FLORBETAPIR IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, e2.205-e2.	1.9	0
93	P1-001: Flutriciclamide ([18F]GE180) Pet: First in Human Pet Study of Novel in Vivo Marker of Human Translocator Protein. , 2016, 12, P397-P397.		0
94	P4-343: Cerebral Brain Perfusion in Cognitively Normal Advanced Elderly (79-93 Years) Measured with Arterial Spin Labelling and [18F]Flutemetamol PET: A Cross Modality Comparison. <i>Alzheimer's and Dementia</i> , 2016, 12, P1166.	0.8	0
95	[P1-123]: STRATEGIES TO DEVELOP PARAMETRIC MAPS FOR TSPO PET TRACER [11C]PBR28 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P288.	0.8	0
96	[P1-124]: REGIONAL KINETIC MODELLING APPLICATION FOR TSPO PET TRACER [11C]PBR28. <i>Alzheimer's and Dementia</i> , 2017, 13, P289.	0.8	0
97	[O3-09-06]: MICROGLIAL ACTIVATION IN ALZHEIMER'S DISEASE DETECTED BY NOVEL THIRD GENERATION TRANSLOCATOR PROTEIN TRACER FLUTRICICLAMIDE ([18F]GE180). <i>Alzheimer's and Dementia</i> , 2017, 13, P922.	0.8	0
98	P1-475: NOVEL THIRD GENERATION MICROGLIAL MARKER FLUTRICICLAMIDE ([18F]GE180) IN ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2018, 14, P506.	0.8	0
99	O5-01-02: VOXEL-LEVEL INTERACTION BETWEEN NFT AND AMYLOID INFLUENCES/PREDICTS THE DECLINE RATE OF COGNITION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2018, 14, P1636.	0.8	0
100	Quantitative Diffusion Tensor Imaging (DTI) Analysis Reveals Different Infiltrative Patterns of Oligodendrogliomas and Astrocytomas in Peri-Tumour White Matter. <i>Neurosurgery</i> , 2019, 84, E273-E273.	1.1	0